CN103784398A - Oxiracetam composition with dehydrating and urination promoting effects and application thereof - Google Patents
Oxiracetam composition with dehydrating and urination promoting effects and application thereof Download PDFInfo
- Publication number
- CN103784398A CN103784398A CN201410048466.9A CN201410048466A CN103784398A CN 103784398 A CN103784398 A CN 103784398A CN 201410048466 A CN201410048466 A CN 201410048466A CN 103784398 A CN103784398 A CN 103784398A
- Authority
- CN
- China
- Prior art keywords
- oxiracetam
- compositions
- composition
- water
- dehydration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an oxiracetam composition with dehydrating and urination promoting effects and application thereof. The composition is mainly prepared from the following 1,000mL of raw materials in total: 160-200g of oxiracetam, 8.5-9.5g of sodium chloride, and the balance of water for injection. The composition can take effects of dehydrating and promoting urination quickly, has a long-lasting action of reducing intracranial pressure, is convenient to use, can pass through blood-brain barrier, but not enter brain cells, thereby avoiding increase of intracranial pressure. The composition is convenient in administration, does not crystallize at room temperature, and is suitable for sudden-onset disasters at ordinary times and cold regions, low temperature, wild field and other harsh environments in wartime. The composition can be rapidly discharged via kidneys to generate good urination promoting effect, has no renal function damage and other side effects, and has good water solubility, high solubility, no toxicity, high safety and no tolerance or accumulated side effects after repeated administration. The composition can be used for emergency and severe disease rescue, improving brain metabolism, promoting consciousness, and accelerating recovery of cognition and limb function after injuries, and has multiple-effect characteristic.
Description
Technical field
The present invention relates to field of medicinal compositions, particularly relate to a kind of oxiracetam compositions and application thereof with dehydration and diuresis functions.
Background technology
Oxiracetam (Oxiracetam), chemical name: Esomeprazole, can make senile cell vigor strengthen, significantly improve brain memory, effective to senile memory and mental deterioration.Be applicable to clinically brain function incomplete, memory disorder, strategic point is the progress of senile dementia only.In recent years, home and abroad research worker is also found, the feature of the anti-platelet aggregation of oxiracetam ex hoc genus anne medicine and change erythrocyte deformability.
Cerebral trauma, cerebral hemorrhage, cerebral infarction, meningitis, the cerebral tumor etc. are sick and wounded, and after cerebral surgery operation, and patient is because brain essence edema or occupying lesion occur that intracranial pressure in various degree raises.And the degree of intracranial hypertension and persistent period have great impact on lapsing to of disease with prognosis, should treat timely and effectively and emergency processing.At present, the dehydration and diuresis medicine that the intracranial pressure that and operation sick and wounded for this kind causes raises is mainly the penetrating agent diuresis such as mannitol.But not only consumption is large for this class medicine, and need quick intravenous drip, this has increased circulation volume and cardiac load is increased, totally unfavorable to the patient of core function badness.Mannitol is supersaturated solution simultaneously, under room temperature, gets final product crystallization, and the thawing crystallization of must heating before use, had so not only bothered but also incured loss through delay and rob emergency, danger, patient with severe symptoms's time, had also increased medical personnel's labor intensity.Because 20% mannitol is supersaturated solution, enter in body and can form crystallite at kidney, oppress, stop up renal tubules, cause renal tubular epithelial edema, degeneration, even downright bad, cause renal function injury.Make the clinical practice of mannitol be subject to great restriction, therefore, need the dehydration and diuresis medicine that a kind of energy substitutes mannitol and evades its side effect badly.
In addition, in cardiovascular surgery and Craniocerebral Surgery, for reducing blood vessel wall tension force, reduce the hemorrhage of incised tissue, often use nitroglycerin and sodium nitroprusside, this has become a kind of conventional operation method, this can make patient's Blood pressure drop, be called as " controlled hypotension ", but can produce the side effect that intracranial pressure raises simultaneously, this side effect to anesthesia of patient after after recovery and major operation the recovery of whole body function bring adverse effect.Therefore, need a kind of effect that neither hinders the controlled hypotension that nitroglycerin and sodium nitroprusside cause badly, can resist again it and produce the method for intracranial pressure rising side effect.
Summary of the invention
Based on this, the object of the present invention is to provide a kind of oxiracetam compositions and application thereof with dehydration and diuresis functions.
The concrete technical scheme solving the problems of the technologies described above is as follows:
An oxiracetam compositions with dehydration and diuresis functions, described compositions is mainly prepared from by the raw material of following weight:
Oxiracetam: 160g-200g,
Sodium chloride: 8.5g-9.5g,
Water for injection adds to 1000mL.
In some embodiment, described compositions is mainly prepared from by the raw material of following weight therein:
Oxiracetam: 195-200g,
Sodium chloride: 9g,
Water for injection adds to 1000mL.
In some embodiment, described compositions also comprises at least one in mannitol, β-Sodium Aescinate, furosemide, dexamethasone, phenobarbital, glycerol, nitroglycerin, sodium nitroprusside or vitamin E therein.
In some embodiment, described compositions also comprises the mannitol of 35g-45g therein.
In some embodiment, described compositions also comprises β-Sodium Aescinate of 9mg-11mg therein.
In some embodiment, described compositions also comprises the furosemide of 190mg-210mg therein.
In some embodiment, described compositions also comprises the dexamethasone of 190mg-210mg therein.
In some embodiment, described compositions also comprises the phenobarbital of 0.9g-1.1g therein.
In some embodiment, described compositions also comprises the glycerol of 90g-110g therein.
In some embodiment, described compositions also comprises the nitroglycerin of 9.9mg-11mg therein.
In some embodiment, described compositions also comprises the sodium nitroprusside of 49mg-51mg therein.
In some embodiment, described compositions also comprises the vitamin E of 195-205mg therein.
In some embodiment, described compositions also comprises 40g mannitol, 10mg β-Sodium Aescinate, 200mg furosemide, 200mg dexamethasone, 1g phenobarbital, 100g glycerol, 10mg nitroglycerin, 50mg sodium nitroprusside or vitamin E2 00mg therein.
In some embodiment, described compositions comprises 24-26g mannitol, 98-102mg dexamethasone and 98-102mg furosemide therein.
Above-mentioned oxiracetam compositions is in the application of preparing in dehydration and diuresis medicine.
Of the present invention a kind ofly have the oxiracetam compositions of dehydration and diuresis functions and application has the following advantages and beneficial effect:
Compositions dehydration of the present invention is rapid-action, it is lasting that the effect of cranium pressure is fallen, application is convenient, can pass through blood brain barrier, but do not enter in brain cell, can not cause that intracranial pressure increases (" knock-on " phenomenon occurs) once again, crystallization not under room temperature, be applicable at ordinary times burst fire-disaster and wartime Han Qu, low temperature, under the adverse circumstances such as field, use, can also produce good diuresis through kidney discharge fast, the side effect such as absent renal function infringement, said composition good water solubility, dissolubility is high, nontoxic, long-time application does not produce tolerance and the side effect such as accumulates, can repeated multiple times a large amount of uses, both can be used for urgency, danger, serious symptom rescue, can improve again brain metabolism short awake, accelerated the rehabilitation of sick and wounded rear cognition and limb function, had the advantages that to obtain multiple-effect with a medicine.
The specific embodiment
Below with reference to specific embodiment, the present invention will be further described.
Embodiment 1
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight:
Oxiracetam: 200g,
Sodium chloride: 9g,
Water for injection adds to 1000mL.
Compound method is: oxiracetam, sodium chloride are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Embodiment 2
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight:
Oxiracetam: 160g,
Sodium chloride: 9g,
Mannitol 40g,
Water for injection adds to 1000mL.
Compound method: oxiracetam, sodium chloride and mannitol are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Embodiment 3
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight:
Oxiracetam: 200g,
Sodium chloride: 9g,
Furosemide 200mg,
Water for injection adds to 1000mL.
Compound method is: oxiracetam, sodium chloride and furosemide are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Embodiment 4
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight:
Oxiracetam: 200g,
Sodium chloride: 9g,
Dexamethasone 200mg,
Water for injection adds to 1000mL.
Compound method is: oxiracetam, sodium chloride and dexamethasone are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Embodiment 5
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight:
Oxiracetam: 200g,
Sodium chloride: 9g,
Phenobarbital 1g,
Water for injection adds to 1000mL.
Compound method is: oxiracetam, sodium chloride and phenobarbital are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Embodiment 6
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight:
Oxiracetam: 200g,
Sodium chloride: 9g,
Glycerol 100g,
Water for injection adds to 1000mL.
Compound method is: oxiracetam, sodium chloride and glycerol are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Embodiment 7
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight:
Oxiracetam: 160g,
Sodium chloride: 9g,
β-Sodium Aescinate 10mg,
Water for injection adds to 1000mL.
Compound method is: oxiracetam, sodium chloride and β-Sodium Aescinate are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Embodiment 8
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight:
Oxiracetam: 160g,
Sodium chloride: 9g,
Nitroglycerin 10mg,
Water for injection adds to 1000mL.
Compound method is: oxiracetam, sodium chloride and nitroglycerin are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Embodiment 9
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight:
Oxiracetam: 160g,
Sodium chloride: 9g,
Sodium nitroprusside 50mg,
Water for injection adds to 1000mL.
Compound method is: oxiracetam, sodium chloride and sodium nitroprusside are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Embodiment 10
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight: oxiracetam 160g, sodium chloride 9g, vitamin E2 00mg, water for injection adds to 1000mL.
Compound method: oxiracetam, sodium chloride and vitamin E are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃ Celsius, 30min steam sterilization.
Embodiment 11
An oxiracetam compositions with dehydration and diuresis functions, described compositions is prepared from by the raw material of following weight: oxiracetam 160g, sodium chloride 9g, 20g mannitol, 100mg dexamethasone and 100mg furosemide, water for injection adds to 1000mL.
Compound method: oxiracetam, sodium chloride, mannitol, dexamethasone and furosemide are dissolved with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
The evaluation of oxiracetam compositions dehydration and diuresis effect
One, experiment purpose
Evaluate the dehydration and diuresis effect of the oxiracetam compositions described in the various embodiments described above by relative analysis.
Two, experimental technique
Experimental group and matched group are set, and wherein, the various embodiments described above are experimental group, and matched group 1 is conventional diuresis dehydrant 20% formula mannitol injection liquid;
Matched group 2: the component of this matched group is: piracetam 200g, sodium chloride 9g, water for injection add to 1000mL; Compound method: dissolve by piracetam, sodium chloride, with 2/3 water for injection, stir, then add to the full amount of water for injection, add activated carbon decolorizing 30 minutes, filter de-carbon, survey semi-finished product content, adjust pH is between 5.5-6.7, fine straining, must clarify medicinal liquid, embedding, through 100 ℃, 30min steam sterilization.
Osmotic pressure, diuresis and the concentration of comparative experiments group and matched group.
Three, experimental result
Result is referring to table 1:
The comparison of table 1 oxiracetam compositions and mannitol, piracetam dehydration and diuresis effect
As known from Table 1, compared with matched group 1 (20% mannitol), the diuresis dehydration of embodiment 1-11 oxiracetam compositions is better than matched group 1 (20% mannitol) or suitable with its drug effect; Relatively its dehydration and diuresis drug effect is suitable with matched group 2, but oxiracetam dosage used reduces much relatively.
The above embodiment has only expressed several embodiment of the present invention, and it describes comparatively concrete and detailed, but can not therefore be interpreted as the restriction to the scope of the claims of the present invention.It should be pointed out that for the person of ordinary skill of the art, without departing from the inventive concept of the premise, can also make some combined deformation and expand and improve, these all belong to protection scope of the present invention.Therefore, the protection domain of patent of the present invention should be as the criterion with claims.
Claims (7)
1. an oxiracetam compositions with dehydration and diuresis functions, is characterized in that, described compositions is mainly prepared from by the raw material of following weight:
Oxiracetam: 160g-200g,
Sodium chloride: 8.5g-9.5g,
Water for injection adds to 1000mL.
2. the oxiracetam compositions with dehydration and diuresis functions according to claim 1, is characterized in that, described compositions is mainly prepared from by the raw material of following weight:
Oxiracetam: 195-200g,
Sodium chloride: 9g,
Water for injection adds to 1000mL.
3. the oxiracetam compositions with dehydration and diuresis functions according to claim 1 and 2, it is characterized in that, described compositions also comprises at least one in mannitol, β-Sodium Aescinate, furosemide, dexamethasone, phenobarbital, glycerol, nitroglycerin, sodium nitroprusside or vitamin E.
4. the oxiracetam compositions with dehydration and diuresis functions according to claim 1 and 2, it is characterized in that, described compositions also comprises 35g-45g mannitol, 9mg-11mg β-Sodium Aescinate, 190mg-210mg furosemide, 190mg-210mg dexamethasone, 0.9g-1.1g phenobarbital, 90g-110g glycerol, 9.9mg-11mg nitroglycerin, 49mg-51mg sodium nitroprusside or vitamin e1 95-205mg.
5. the oxiracetam compositions with dehydration and diuresis functions according to claim 1 and 2, it is characterized in that, described compositions also comprises 40g mannitol, 10mg β-Sodium Aescinate, 200mg furosemide, 200mg dexamethasone, 1g phenobarbital, 100g glycerol, 10mg nitroglycerin, 50mg sodium nitroprusside or vitamin E2 00mg.
6. the oxiracetam compositions with dehydration and diuresis functions according to claim 1 and 2, is characterized in that, described compositions also comprises 24-26g mannitol, 98-102mg dexamethasone and 98-102mg furosemide.
7. the oxiracetam compositions as described in claim 1-6 any one is in the application of preparing in dehydration and diuresis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410048466.9A CN103784398A (en) | 2014-02-11 | 2014-02-11 | Oxiracetam composition with dehydrating and urination promoting effects and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410048466.9A CN103784398A (en) | 2014-02-11 | 2014-02-11 | Oxiracetam composition with dehydrating and urination promoting effects and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103784398A true CN103784398A (en) | 2014-05-14 |
Family
ID=50660742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410048466.9A Pending CN103784398A (en) | 2014-02-11 | 2014-02-11 | Oxiracetam composition with dehydrating and urination promoting effects and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103784398A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104000815A (en) * | 2014-06-13 | 2014-08-27 | 石药集团欧意药业有限公司 | Pharmaceutical composition containing 4-hydroxide radical-2-oxo-1-pyrrolidine acetamide and application thereof |
| CN108498729A (en) * | 2018-05-28 | 2018-09-07 | 暨南大学附属第医院（广州华侨医院） | A kind of pharmaceutical composition and its preparation method and application of therapeutic radiation injury of kidney |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1424034A (en) * | 2002-12-03 | 2003-06-18 | 诸葛华明 | Preparing method of oxiracetam injection and products thereof |
| CN102525899A (en) * | 2012-01-17 | 2012-07-04 | 山东罗欣药业股份有限公司 | Injection solution of oxiracetam composition and preparation method thereof |
-
2014
- 2014-02-11 CN CN201410048466.9A patent/CN103784398A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1424034A (en) * | 2002-12-03 | 2003-06-18 | 诸葛华明 | Preparing method of oxiracetam injection and products thereof |
| CN102525899A (en) * | 2012-01-17 | 2012-07-04 | 山东罗欣药业股份有限公司 | Injection solution of oxiracetam composition and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 伍三妹等: "奥拉西坦治疗38例急性颅脑损疗效观察", 《中国实用医药》, vol. 3, no. 25, 30 September 2008 (2008-09-30), pages 123 - 124 * |
| 张涛: "奥拉西坦治疗轻中型脑伤疗效的神经电生理研究", 《中国优秀博硕士学位论文全文数据库（硕士）医药卫生科技辑》, no. 5, 15 September 2005 (2005-09-15), pages 066 - 33 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104000815A (en) * | 2014-06-13 | 2014-08-27 | 石药集团欧意药业有限公司 | Pharmaceutical composition containing 4-hydroxide radical-2-oxo-1-pyrrolidine acetamide and application thereof |
| CN104000815B (en) * | 2014-06-13 | 2016-09-14 | 石药集团欧意药业有限公司 | A kind of pharmaceutical composition containing Esomeprazole and application thereof |
| CN108498729A (en) * | 2018-05-28 | 2018-09-07 | 暨南大学附属第医院（广州华侨医院） | A kind of pharmaceutical composition and its preparation method and application of therapeutic radiation injury of kidney |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101402565B (en) | Halogenated 2-(a-hydroxyl pentyl) benzoate, production method and uses thereof | |
| KR101801700B1 (en) | Hydroxysafflor yellow a sodium and preparation as well as application thereof | |
| DE112013003596T5 (en) | Compositions comprising crosslinked cation-binding polymers and their use | |
| CN103784398A (en) | Oxiracetam composition with dehydrating and urination promoting effects and application thereof | |
| Lopes | Enteral fluid therapy | |
| JP2013537170A (en) | 5α-androstane-3β, 5,6β-triol injection and preparation method thereof | |
| CN104546809B (en) | Application of 3,3 ', 5,5 '-tetra isopropyls-the 4,4 '-bigeminy phenol in preventing and treating cerebral arterial thrombosis | |
| CN101327200B (en) | Glycerol fruit sugar injection and preparation method thereof | |
| HUE029614T2 (en) | Pharmaceutical Compositions For Dehydrating, Atrophying And Eliminating Pathological Tissues | |
| CN101947247B (en) | Method for preparing ginkgodipyidamolum injection | |
| KR100945780B1 (en) | Vasodilator comprising extract of Sargassum micracanthum, extract of Sargassum yezoense and sargahydroquinoic acid | |
| CN102988461A (en) | Rhodiola rosea injection and preparation method thereof | |
| KR101788658B1 (en) | New hydroxysafflor yellow a salt for pharmaceutical formulation | |
| CN104523734B (en) | It is a kind of to treat cerebral infarction or/and treating coronary heart disease and angina pectoris composition and its preparation method and application | |
| CN103058999A (en) | Novel pantoprazole sodium compound and pharmaceutical composition thereof | |
| CN102652755B (en) | Mannitol sodium chloride injection and preparation method thereof | |
| CN104000836B (en) | A kind of antithrombotic pharmaceutical composition and application thereof | |
| CN101491495A (en) | Salvianolic acid B magnesium injection, preparation method and use thereof | |
| CN106822284A (en) | A kind of medicine for treating irregular menstruation | |
| WO2015172607A1 (en) | Yunnan baiyao nanoemulsion and preparation method | |
| CN105412136B (en) | It is a kind of to be used to treat the composition of ischemic angiocardiopathy and cerebrovascular disease and its medicine of preparation and application | |
| CN1732964A (en) | Pharmaceutical composition, its preparation process and usage | |
| CN105982877B (en) | Puerarin nano crystal capsule and preparation method thereof | |
| CN110585210B (en) | Application of sparganium stoloniferum A in preparation of anti-ischemic cerebral apoplexy medicines | |
| Hanefeld-Fox et al. | Sacubitril/Valsartan-Associated Small Bowel Ileus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140514 |